CE Mark for EyeArt software for automatic detection of diabetic retinopathy- Eyenuk Inc.

Eyenuk, Inc. announced that it received CE Marking for its pioneering EyeArt software, a suite of advanced image analysis tools for automated high-throughput screening of diabetic retinopathy. The company plans to launch its product in select leading eye care sites across Europe in the next few months.

Previous research on diabetic retinopathy (DR) has yielded sufficient evidence that microaneurysm (MA> turnover rates are a good predictor of likelihood of progression to more severe retinopathy, establishing MA turnover as an excellent biomarker for DR. The availability of a reliable tool like EyeMark to measure this biomarker automatically from images will have high positive influence on various aspects of DR care, including screening, monitoring progression, drug discovery and clinical research.